Near-Infrared Fluorescence Imaging of Non-Hodgkin’s Lymphoma CD20 Expression Using Cy7-Conjugated Obinutuzumab

被引:0
作者
Xinfeng Lin
Hua Zhu
Zheng Luo
Ye Hong
Hong Zhang
Xijuan Liu
Huirong Ding
Huifang Tian
Zhi Yang
机构
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Nuclear Medicine
[2] China Institute of Atomic Energy,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Central Laboratory
[3] Peking University Cancer Hospital & Institute,undefined
来源
Molecular Imaging and Biology | 2014年 / 16卷
关键词
Near-infrared fluorescence imaging; Cyanine dye indotricarbocyanine; CD20; Obinutuzumab; Non-Hodgkin’s lymphoma;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:877 / 887
页数:10
相关论文
共 107 条
[1]  
Siegel R(2013)Cancer statistics, 2013 CA: A Cancer Journal for Clinicians 63 11-30
[2]  
Naishadham D(2007)The non-Hodgkin lymphomas: a review of the epidemiologic literature Int J Cancer 120 1-39
[3]  
Jemal A(2005)B cell non-Hodgkin’s lymphoma: rituximab safety experience Arthritis Res Ther 7 S19-S25
[4]  
Alexander DD(1994)CD20: a regulator of cell-cycle progression of B lymphocytes Immunol Today 15 450-454
[5]  
Mink PJ(2008)CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins J Biol Chem 283 18545-18552
[6]  
Adami HO(2013)TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20 Oncogene 32 2096-2106
[7]  
Mohrbacher A(1988)Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains EMBO J 7 711-717
[8]  
Tedder TF(1987)Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas Blood 69 584-591
[9]  
Engel P(1984)Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation Blood 63 1424-1433
[10]  
Polyak MJ(2002)Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia Leuk Lymphoma 43 149-151